Ligand Pharmaceuticals Inc expected to post earnings of 78 cents a share - Earnings Preview

Ligand Pharmaceuticals Incorporated

04/05/2024 04:00

* Ligand Pharmaceuticals Inc  LGND.OQ   LGND.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 7 for the period ending March 31 2024
    * The Jupiter Florida-based  company is expected to report a
36.5% decrease in revenue to $27.924 million from $43.98 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Ligand Pharmaceuticals
Inc is
for earnings of 78 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $110.00​, above​ its last closing price
of $73.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.66        0.66       1.38      Beat    108.9
 Sep. 30 2023  0.60        0.61       1.02      Beat    67.2
 Jun. 30 2023  0.64        0.64       1.42      Beat    122​
 Mar. 31 2023  0.95        0.89       2.28      Beat    155
 ​​Dec.        1.18        1.19       1.36      Beat    14
 31 2022                                                
 Sep. 30 2022  0.44        0.43       1.31      Beat    203.4​
 Jun. 30 2022  0.46        0.43       1.03      Beat    139.5
 Mar. 31 2022  0.66        0.66       0.58      Missed  -11.7
 This summary was machine generated May 4 at 03:00 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)